
WHAT IS CLAIMED IS:

1. A compound of formula (I):



(I)

wherein

n is 0, 1 or 2;

R^1 is selected from hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy, amino, nitro, halo, cyano, hydroxy, and trifluromethyl;

each R^2, when present, is independently selected from C_{1-4} alkyl, C_{1-3} alkoxy, amino, nitro, halo, cyano, hydroxyl, and trifluromethyl;

R^3 is hydrogen, methyl or ethyl;

R^4 is hydrogen, methyl or ethyl;

or a pharmaceutically-acceptable salt thereof.

2. The compound of Claim 1, or a pharmaceutically-acceptable salt thereof, wherein R^1 is hydrogen.


3. The compound of Claim 1, or a pharmaceutically-acceptable salt thereof, wherein R^1 is nitro.

4. The compound of Claim 1, or a pharmaceutically-acceptable salt thereof, wherein R^1 is amino.

5. The compound of Claim 1, or a pharmaceutically-acceptable salt thereof, wherein *n* is 0.

6. The compound of Claim 1, or a pharmaceutically-acceptable salt thereof, wherein *n* is 1.

7. A compound of formula (II):



(II)

wherein

R^1 is selected from hydrogen, C_{1-4} alkyl, C_{1-3} alkoxy, amino, nitro, halo, cyano, hydroxy, and trifluromethyl;


or a pharmaceutically-acceptable salt thereof.

8. The compound of Claim 7, or a pharmaceutically-acceptable salt thereof, wherein R^1 is selected from hydrogen, methyl, methoxy, amino, nitro, and chloro.

9. The compound of Claim 7, or a pharmaceutically-acceptable salt thereof, wherein R^1 is hydrogen.

10. The compound of Claim 7, or a pharmaceutically-acceptable salt thereof, wherein R^1 is amino.


11. A compound of formula **1:**



1

or a pharmaceutically acceptable salt thereof.


12. The compound of Claim 11, wherein the compound is



.

13. A pharmaceutical composition comprising a pharmaceutically acceptable-carrier and a compound of any one of Claims 1 to 12.

14. A process for preparing a compound of Claim 1, the process comprising deprotecting a compound of formula (I-A):




(I-A)

or a salt thereof; wherein R^1, R^2, R^3, R^4 and *n* are as defined in Claim 1; each PG^a is independently a hydroxyl protecting group; and PG^b is a carboxyl protecting group; to provide a compound of formula (I) or a pharmaceutically acceptable salt thereof.

15. The process of Claim 14, wherein R^1 is nitro; R^3 and R^4 are methyl; each PG^a is acetyl; PG^b is methyl; and *n* is 0.


16. A process for preparing a compound of Claim 11, or a pharmaceutically acceptable salt thereof, the process comprising:

(a) reacting a compound of formula **12'**:




12'

or a salt thereof; wherein each PG^a is independently a hydroxyl protecting group, with a compound of formula **13:**



13

to provide a compound of formula **14'**:




14'

and

(b) deprotecting the compound of formula **14'** to provide the compound of formula **1** or a pharmaceutically acceptable salt thereof.

17. A compound of formula **13**:



13

or a salt thereof.

18. Use of a compound of any one of Claims 1 to 12 for the manufacture of a medicament for the treatment of gastrointestinal inflammatory disease in a mammal.

19. The use of Claim 18, wherein the gastrointestinal inflammatory disease is ulcerative colitis.

20. The use of Claim 18, wherein the gastrointestinal inflammatory disease is Crohn's disease.

21. The use of Claim 18, wherein the gastrointestinal inflammatory disease is colitis associated with immune checkpoint inhibitor therapy.